Drug intelligence / Profile preview

qihuang jianpi zishen

Development stage: Unknown
Lead developer: First Affiliated Hospital of Anhui University of Chinese Medicine
Administration: Oral

Overview

Qihuang Jianpi Zishen Granules is a Traditional Chinese Medicine (TCM) formulation developed by The First Affiliated Hospital of Anhui University of Chinese Medicine. It is specifically indicated for the treatment of systemic lupus erythematosus (SLE), targeting patients with the 'Spleen and Kidney Deficiency' syndrome pattern. The formulation's name suggests it contains ingredients to tonify Qi (likely *Astragalus*), strengthen the spleen (Jianpi), and nourish the kidney (Zishen). It is currently being investigated in a multicenter, double-blind, randomized controlled clinical trial to evaluate its efficacy and safety in patients with mild SLE.

Other names: Qihuang Jianpi Zishen Granules

Beyond the preview

Go deeper on qihuang jianpi zishen.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on qihuang jianpi zishen.

Explore the full profile